Live intraday price
Compare with our price levels
Close 2026-09-30: $223.53 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Not in the buy zone yet — needs to drop 3.2% · 2 whales recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 2.9Moves ~$5.24 a day
⚖️ Positives and risks
- ●เซียนซื้อใหม่/ซื้อเพิ่มไตรมาสล่าสุด 2 ราย
- ●นักวิเคราะห์ส่วนใหญ่แนะนำ Buy
- ●เซียนขายออก/ลดสัดส่วน 1 ราย: Joel Greenblatt (ลด)
- ●แนวโน้มระยะยาวเป็นขาลง (ใต้ MA200 และ MA200 ชี้ลง)
- ●อ่อนแอกว่าตลาด (S&P 500) -19% ใน 6 เดือน
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
Farrell Michael J. · CEO · Chair · Director
2026-09-08 · 4,991 shares @ $222.44 · pre-planned sale (10b5-1)
FARRELL PETER C · Director
2026-09-02 · 970 shares @ $234.73 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-08-07 · 4,991 shares @ $205.69 · pre-planned sale (10b5-1)
FARRELL PETER C · Director
2026-08-05 · 8,000 shares @ $225.00 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-07-07 · 4,991 shares @ $218.55 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-06-08 · 4,991 shares @ $193.96 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-05-07 · 4,991 shares @ $207.82 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-04-07 · 4,991 shares @ $225.50 · pre-planned sale (10b5-1)
FARRELL PETER C · Director
2026-04-01 · 2,000 shares @ $225.00 · pre-planned sale (10b5-1)
Sandercock Brett · CFO
2026-04-01 · 1,000 shares @ $224.31 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-03-09 · 4,991 shares @ $251.03 · pre-planned sale (10b5-1)
FARRELL PETER C · Director
2026-03-04 · 2,000 shares @ $260.22 · pre-planned sale (10b5-1)
Sandercock Brett · CFO
2026-03-02 · 1,000 shares @ $254.30 · pre-planned sale (10b5-1)
Farrell Michael J. · CEO · Chair · Director
2026-02-09 · 4,991 shares @ $273.78 · pre-planned sale (10b5-1)
FARRELL PETER C · Director
2026-02-04 · 2,000 shares @ $251.31 · pre-planned sale (10b5-1)
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
MarketBeat · 2026-09-21
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
Insider Monkey · 2026-09-19
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Barrons.com · 2026-09-15
This Analyst Just Upgraded ResMed Stock. Here's Why.
Barchart · 2026-09-15
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
Simply Wall St. · 2026-09-15
🔬 Deep dive
For those who want the detailed numbers